Akebia Therapeutics, Inc. (NASDAQ:AKBA) is the subject of a new 13D filing issued by Kearny Venture Partners LP, which reveals the most up-to-date ownership information of the investment firm in the stock, which you can see in the table below. 13D filings indicate an activist position, which means that the filer may make efforts to engage the company’s management and/or board of directors and make recommendations as to ways to improve the company’s operations and enhance the stock’s value to shareholders. Any such transmissions are often disclosed in 13D filings and may be found in the embedded filing below.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| . Kearny Venture Partners, L.P. ( KVP )2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) x | 1,560,309 | 4.0% | ||||
| . Kearny Venture Partners Entrepreneurs Fund, L.P. ( KVPE )2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) x | 0.1% | |||||
| . Thomas Weisel Healthcare Venture Partners, L.P. ( TWHVP )2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) x | 0.0% | |||||
| . Kearny Venture Associates, L.L.C. ( KVA )2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) x | 4.1% | |||||
| . Caley Castelein ( Castelein )2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) x | 4.2% | |||||
| . Richard Spalding ( Spalding )2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) x | 4.1% | |||||
| . James Shapiro ( Shapiro )2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) x | 4.1% |
Page 1 of 10 SEC Filing
| CUSIP NO. 00972D105 | 13D/A | Page 1 of 10 |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
(RULE 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT
TO RULE 13d-2(a)
(Amendment No. 1)*
Akebia Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00972D105
(CUSIP Number)
Andrew Jensen
Kearny Venture Partners
One Maritime Plaza, Suite 1975
San Francisco, CA 94111
(415) 875-7777
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
COPY TO:
Sean Caplice
c/o Gunderson Dettmer Stough Villeneuve
Franklin & Hachigian, LLP
1200 Seaport Blvd., Redwood City, CA 94063
(650) 463-5254
January 8, 2016
(Date of Event Which Requires Filing of
This Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because
of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨
Note: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom
copies are to be sent.
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
This information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
